Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.
1-Methylpropyl-2-imidazolyl disulfide (MID) is a novel antitumor agent currently in Phase I clinical trials. The chromatographic behavior of MID and its potential impurity, degradation product, and metabolite 2-mercaptoimidazole (2MI) was studied under reversed-phase (RP) and normal-phase (NP) conditions. Both RP- and NP-HPLC separation methods were developed. RP-HPLC was validated as a stability-indicating assay for MID. NP-HPLC retained both MID and 2MI and pending further validation, could prove useful in the study of MID pharmacokinetics.
Hashash
Ahmad
A
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.
Kirkpatrick
D Lynn
DL
Egorin
Merrill J
MJ
Block
Lawrence H
LH
Lazo
John S
JS
D000970:Antineoplastic Agents / Q000097:blood* / Q000493:pharmacokinetics; D002021:Buffers; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004220:Disulfides / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007093:Imidazoles / Q000097:blood* / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000970:Antineoplastic Agents; D002021:Buffers; D004220:Disulfides; D007093:Imidazoles; C412893:1-methylpropyl-2-imidazolyl disulfide